The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 40.00
Ask: 43.00
Change: 0.00 (0.00%)
Spread: 3.00 (7.50%)
Open: 41.50
High: 41.50
Low: 41.50
Prev. Close: 41.50
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Elute Intelligence Patent Reader launched

1 Sep 2020 07:00

RNS Number : 5446X
Frontier IP Group plc
01 September 2020
 

RNS REACH

AIM: FIPP

01 September 2020

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

Portfolio news - Elute Intelligence ground breaking Patent Reader launched commercially

 

 

Frontier IP, a specialist in commercialising intellectual property, notes the following announcement from portfolio company Elute Intelligence Holdings Limited ("Elute" or the "Company") that it is to launch its innovative Patent Reader product commercially.

The move follows a successful pilot with a dedicated user group comprising of members from multinationals, high-tech SMEs and professional intellectual property service providers.

Elute launched a dedicated COVID-19 Document Reader earlier this year to help scientists researching the disease find relevant documents more swiftly and easily.

Frontier IP holds a 43.5 per cent equity stake in the Company.

 

 

Elute Intelligence statement begins:

 

Elute Intelligence Holdings ground breaking Patent Reader launched commercially

01 September 2020 Elute Intelligence Holdings ("Elute" or the "Company") is to make patent searching quicker and easier with the commercial launch of a Patent Reader based on its novel software tools, which mimics the way people read, to intelligently search and compare unstructured text-based information.

The move follows a successful pilot with a dedicated user group comprising patent rich multi-nationals, high-tech SMEs and professional IP service providers, such as lawyers, established to support the Patent Reader's development.

The Patent Reader allows users to identify relevant patents and understand why they are relevant within minutes of starting a search. Initially, they will be able to search from more than 70 million patents in major jurisdictions, including the United States, China, the European Union and worldwide.

It is one of many potential applications for Elute's technology. The Company's software searches, compares and analyses documents to identify similarities between them by mimicking the way people read. Users are able to enter existing patents, draft applications, research papers on topics of interest and identify relevant patents. This means the approach is very different to conventional keyword or Boolean search technologies. A patent application has been filed to protect developments of the technology.

Elute was incorporated last year from an existing UK business CFL Software Limited and included complementary intellectual property developed by Frontier IP. Existing customers include the Universities and Colleges Admissions Service ("UCAS") which is using a version of the software called Copycatch to detect plagiarism in students' personal statements. Others include academic institutions, commercial researchers and lawyers.

 

Peter Fischer, Chief Executive Officer of Elute Intelligence, said: "We believe that Patent Reader has the ability to profoundly change the way patent search is carried out with huge benefits to our customers. I would like to thank the user group for its support and feedback, which has proved invaluable in allowing us to refine the product."

 Matthew White, Chief Commercialisation Officer of Frontier IP Group, said: "We are delighted with the very rapid progress being made by Elute since we started working with them last year. The Company's unique technology has a very broad range of applications. The Patent Reader is among the first products to take advantage of its immense potential."

 

 

Elute Intelligence Holdings statement ends

 

 

ENQUIRIES

Frontier IP Group Plc

T: 020 7332 2338

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

neil@frontierip.co.uk

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser)

T: 0203 328 5656

Nick Athanas / James Hornigold

 

 

 

 

 

 

 

 

 

 

ABout frontier IP Group

Frontier IP unites science, finance and industry to build businesses based on outstanding research. It identifies strong intellectual property and accelerates its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

About RNS Reach announcements

This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Private Policy.
 
END
 
 
NRAWPUWWRUPUGMG
Date   Source Headline
6th Dec 20196:25 pmRNSHolding(s) in Company
5th Dec 201912:00 pmRNSHolding(s) in Company
4th Dec 201912:00 pmRNSResult of AGM & Total Voting Rights
26th Nov 201912:58 pmRNSHolding(s) in Company
13th Nov 20195:00 pmRNSPosting of Annual Report and Accounts
7th Nov 201912:20 pmRNSHolding(s) in Company
6th Nov 20192:00 pmRNSResult of Placing
6th Nov 20197:01 amRNSProposed fundraising of £3.5m by way of Placing
6th Nov 20197:00 amRNSFinal Results
22nd Oct 20197:00 amRNSAppointment of senior advisers
15th Oct 20197:00 amRNSNew portfolio company: Elute Intelligence Holdings
10th Sep 20197:00 amRNSAppointment of Broker
25th Jul 20197:00 amRNSExscientia collaboration with Rallybio
15th Jul 201912:08 pmRNSHolding(s) in Company
14th Jun 20197:00 amRNSExscientia partnership with GT Apeiron
31st May 20195:00 pmRNSTotal Voting Rights
31st May 20193:15 pmRNSDirectorate Change
28th May 20197:00 amRNSFieldwork Robotics completes initial field trials
15th May 20197:00 amRNSDirector exercise of options, shareholding and TVR
10th May 201911:48 amRNSHolding(s) in Company
30th Apr 20197:00 amRNSEuropean plan to boost marine & coastal economies
8th Apr 20197:00 amRNSParkside Architectural Tiles launch Alusid range
8th Apr 20197:00 amRNSBosch UK to work with Pulsiv Solar
8th Apr 20197:00 amRNSInvestor event at the Royal Academy of Engineering
4th Apr 20197:00 amRNSExscientia reaches first major milestone with GSK
3rd Apr 20195:51 pmRNSHolding(s) in Company
3rd Apr 20193:45 pmRNSHolding(s) in Company
1st Apr 20197:00 amRNSFieldwork Robotics wins Innovate UK ISCF grant
27th Mar 20191:30 pmRNSHolding(s) in Company
27th Mar 20191:30 pmRNSHolding(s) in Company
27th Mar 20197:00 amRNSBoard Appointment
27th Mar 20197:00 amRNSUnaudited Half Year Results
21st Mar 20199:18 amRNSTrading Update
21st Mar 20199:14 amRNSExscientia & Celgene drug discovery collaboration
6th Mar 20195:15 pmRNSHolding(s) in Company
20th Feb 20197:00 amRNSTVG - key partner in $9.67m DARPA project award
12th Feb 20197:00 amRNSThird Portuguese spin out: Insignals Neurotech
4th Feb 20197:00 amRNSAmprologix wins DHSC backing for new antibiotic
31st Jan 20199:00 amRNSNandi Proteins led consortium wins UK grant
25th Jan 20197:00 amRNSThe Vaccine Group wins Department of Health grant
7th Jan 20191:29 pmRNSExscientia Series B funding & Roche collaboration
27th Dec 20187:00 amRNSMolendotech - Palintest start commercial roll out
19th Dec 201811:45 amRNSResult of AGM
30th Nov 20185:30 pmRNSTotal Voting Rights
23rd Nov 201812:10 pmRNSPosting of Annual Report and Notice of AGM
22nd Nov 20181:12 pmRNSHolding(s) in Company
22nd Nov 201810:36 amRNSHolding(s) in Company
21st Nov 20183:30 pmRNSHolding(s) in Company
21st Nov 201811:00 amRNSTotal Voting Rights and Director/PDMR Shareholding
15th Nov 20184:08 pmRNSDirector Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.